Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

BACKGROUND: Immune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) promotes intratumoral T cell infiltra...

Descripción completa

Detalles Bibliográficos
Autores principales: Subudhi, Sumit K, Siddiqui, Bilal A, Aparicio, Ana M, Yadav, Shalini S, Basu, Sreyashi, Chen, Hong, Jindal, Sonali, Tidwell, Rebecca S S, Varma, Ashwin, Logothetis, Christopher J, Allison, James P, Corn, Paul G, Sharma, Padmanee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524287/
https://www.ncbi.nlm.nih.gov/pubmed/34663638
http://dx.doi.org/10.1136/jitc-2021-002919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524287/
https://www.ncbi.nlm.nih.gov/pubmed/34663638
http://dx.doi.org/10.1136/jitc-2021-002919

Ejemplares similares